title: [Clinical effects of budesonide/formoterol combination drug in elder patients with asthma compared with budesonide plus tulobuterol patch combination treatment].
abstract: OBJECTIVE
  Tulobuterol patch (Tulo) is often used for treatment of elder patient with asthma in Japan. However, there is no evidence either ICS plus Tulo or ICS/LABA combination is better for elder patient.
  
  
  METHODS
  Elder patients with asthma (aged≥ 70, n=17) who had treated with budesonide (BUD) 400 μg/day plus Tulo 2 mg/day, were randomly assigned either to change control medication to budesonide/formoterol combination (BUD/FM) 320/9 μg/day or to keep BUD plus Tulo treatment for 12 weeks.
  
  
  RESULTS
  At week 4 and week 12, the BUD/FM group showed significant increase in lung function (FEV1, %FEV1) and mini AQLQ score compared with the BUD plus Tulo group. The BUD/FM group also showed decrease in Tumor Necrosis Factor-alpha level in exhaled breath condensate at week 12. No adverse event was observed in both groups.
  
  
  CONCLUSIONS
  In elder patients with asthma, treatment with BUD/FM does not have any clinical disadvantage and may provide better efficacy in lung function, QOL, and possibly anti-inflammation compared with BUD plus Tulo treatment.
authors.affiliation: Department of Respiratory Medicine, Mazda Hospital. onari.y@mazda.co.jp
authors.forename: Yojiro
authors.initials: Y
authors.lastname: Onari
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Haruta
authors.forename: Kenichi
authors.initials: K
authors.lastname: Mukaida
authors.forename: Keiichi
authors.initials: K
authors.lastname: Kondoh
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001249:Asthma / Q000175:diagnosis / Q000188:drug therapy*; D015415:Biomarkers / Q000032:analysis; D001944:Breath Tests; D001993:Bronchodilator Agents / Q000008:administration & dosage*; D019819:Budesonide / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D004983:Ethanolamines / Q000008:administration & dosage*; D005260:Female; D000068759:Formoterol Fumarate; D006801:Humans; D008297:Male; D011788:Quality of Life; D013726:Terbutaline / Q000008:administration & dosage / Q000031:analogs & derivatives*; D013997:Time Factors; D057968:Transdermal Patch; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
chemical_list: D015415:Biomarkers; D001993:Bronchodilator Agents; D004983:Ethanolamines; D014409:Tumor Necrosis Factor-alpha; D019819:Budesonide; C010809:tulobuterol; D013726:Terbutaline; D000068759:Formoterol Fumarate